Zongertinib demonstrated promising activity in the brain during the dose-expansion stage, achieving an objective response rate (ORR) of 41% per the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM). “HER2-mutated lung cancer is rare, but brain metastasis is highly prevalent in these patients. Fifty percent of patients who have HER2-mutant [NSCLC] develop brain metastases during their lifetime. This means that despite new treatments developing [for NSCLC], one [being] zongertinib, it is also important to see that these drugs work for brain metastases,” Ruiter said in the interview. So, this is really important to show—that this drug not [only] has a high systemic response rate but also induces responses in the brain,” Ruiter added.